{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:34:11Z","timestamp":1793093651042,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013225","name":"Academy of Scientific and Innovative Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bmcl.2023.129308","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T02:04:21Z","timestamp":1682733861000},"page":"129308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Synthesis of novel ciprofloxacin-avibactam conjugates for the development of second-generation non-\u03b2-lactam-\u03b2-lactamase inhibitors"],"prefix":"10.1016","volume":"88","author":[{"given":"Rahul","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Pathania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-3110","authenticated-orcid":false,"given":"Shashi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemraj","family":"Nandanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-7743","authenticated-orcid":false,"given":"Sushil K.","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129308_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/antibiotics3020193","article-title":"\u03b2-Lactam antibiotics renaissance","volume":"3","author":"Qin","year":"2014","journal-title":"Antibiotics"},{"key":"10.1016\/j.bmcl.2023.129308_b0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.bmcl.2023.129308_b0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129308_b0020","article-title":"The selection and use of essential medicines: report of the WHO expert committee, (including the 20th WHO model list of essential medicines and the 6th model list of essential medicines for children)","author":"WHO","year":"2017","journal-title":"World Health Organization"},{"key":"10.1016\/j.bmcl.2023.129308_b0025","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016."},{"key":"10.1016\/j.bmcl.2023.129308_b0030","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00018-004-4060-9","article-title":"Resistance to \u03b2-lactam antibiotics","volume":"61","author":"Poole","year":"2004","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.bmcl.2023.129308_b0035","first-page":"611","article-title":"Appropriate prescribing of oral beta-lactam antibiotics","volume":"62","author":"Holten","year":"2000","journal-title":"American Family Physician"},{"key":"10.1016\/j.bmcl.2023.129308_b0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/8.1.81","article-title":"The combination of clavulanic acid and amoxycillin (Augmentin) in the treatment of patients infected with penicillinase-producing gonococci","volume":"8","author":"De Koning","year":"1981","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.bmcl.2023.129308_b0045","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bmcl.2023.129308_b0050","doi-asserted-by":"crossref","first-page":"15802","DOI":"10.1021\/acs.jmedchem.0c01535","article-title":"Discovery of ANT3310, a novel broad-spectrum serine \u03b2-lactamase inhibitor of the diazabicyclooctane class, which strongly potentiates meropenem activity against carbapenem-resistant enterobacterales and Acinetobacter baumannii","volume":"63","author":"Davies","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmcl.2023.129308_b0055","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acs.jmedchem.9b01279","article-title":"\u03b2-Lactamase inhibitors to restore the efficacy of antibiotics against superbugs","volume":"63","author":"Gonz\u00e1lez-Bello","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmcl.2023.129308_b0060","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.3390\/ijms21239308","article-title":"New carbapenemase inhibitors: clearing the way for the \u03b2-lactams","volume":"21","author":"V\u00e1zquez-Ucha","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.bmcl.2023.129308_b0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2023.129308_b0070","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Pro. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bmcl.2023.129308_b0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ja.2013.86","article-title":"Antibiotics in the clinical pipeline in 2013","volume":"66","author":"Butler","year":"2013","journal-title":"The Journal of Antibiotics"},{"key":"10.1016\/j.bmcl.2023.129308_b0080","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.bmcl.2023.129308_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/antibiotics8010032","article-title":"Activity of cefepime-zidebactam against multidrug-resistant (MDR) Gram-negative pathogens","volume":"8","author":"Thomson","year":"2019","journal-title":"Antibiotics"},{"key":"10.1016\/j.bmcl.2023.129308_b0090","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1021\/acs.jmedchem.8b00091","article-title":"Strategic approaches to overcome resistance against Gram-negative pathogens using \u03b2-lactamase inhibitors and \u03b2-lactam enhancers: activity of three novel diazabicyclooctanes WCK 5153, zidebactam (WCK 5107), and WCK 4234","volume":"61","author":"Papp-Wallace","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmcl.2023.129308_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.bmcl.2023.129308_b0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1021\/acsinfecdis.9b00031","article-title":"IID572: a new potentially best-in-class \u03b2-lactamase inhibitor","volume":"5","author":"Reck","year":"2019","journal-title":"ACS Infectious Diseases"},{"key":"10.1016\/j.bmcl.2023.129308_b0105","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In Vitro Activity of MK-7655 a Novel \u03b2-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.bmcl.2023.129308_b0110","doi-asserted-by":"crossref","first-page":"01238","DOI":"10.1128\/AAC.01238-17","article-title":"Potent \u03b2-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.bmcl.2023.129308_b0115","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1021\/acs.jmedchem.9b02125","article-title":"Diazabicyclooctane Functionalization for Inhibition of \u03b2-Lactamases from Enterobacteria","volume":"63","author":"Bouchet","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmcl.2023.129308_b0120","first-page":"377","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiology and Molecular Biology Reviews: MMBR"},{"key":"10.1016\/j.bmcl.2023.129308_b0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciy035","article-title":"Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits","volume":"67","author":"Kabbani","year":"2018","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.bmcl.2023.129308_b0130","unstructured":"USE, I.N. Highlights of prescribing information.Population. 2018. 8. 79."},{"key":"10.1016\/j.bmcl.2023.129308_b0135","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1017\/ice.2019.247","article-title":"Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals","volume":"40","author":"Yarrington","year":"2019","journal-title":"Infection Control and Hospital Epidemiology"},{"key":"10.1016\/j.bmcl.2023.129308_b0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","article-title":"A critical review of the fluoroquinolones","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2023.129308_b0145","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41586-018-03267-5","article-title":"When antibiotics turn toxic","volume":"555","author":"Marchant","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129308_b0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1021\/acscombsci.0c00060","volume":"22","author":"Upadhyay","year":"2020","journal-title":"ACS Combinatorial Science"},{"key":"10.1016\/j.bmcl.2023.129308_b0155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/14756360903373350","article-title":"Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects","volume":"25","author":"Sharma","year":"2010","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"key":"10.1016\/j.bmcl.2023.129308_b0160","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic adjuvants: rescuing antibiotics from resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.bmcl.2023.129308_b0165","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/acs.oprd.6b00268","article-title":"Development of a manufacturing route to avibactam, a \u03b2-lactamase inhibitor","volume":"20","author":"Ball","year":"2016","journal-title":"Organic Process Research and Development"},{"key":"10.1016\/j.bmcl.2023.129308_b0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.22159\/ajpcr.2019.v12i9.34712","article-title":"Synthesis, characterization, and biological evaluation of substituted 1,3,4-oxadiazole derivative: derived from ciprofloxacin","volume":"12","author":"Singhai","year":"2019","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"key":"10.1016\/j.bmcl.2023.129308_b0175","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1055\/s-0032-1317544","article-title":"Synthetic Studies towards NG-121: Diastereoselective synthesis of NG-121 methyl ether","volume":"44","author":"Singh","year":"2012","journal-title":"Synthesis"},{"key":"10.1016\/j.bmcl.2023.129308_b0180","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/psc.2968","article-title":"Optimized syntheses of Fmoc azido amino acids for the preparation of azidopeptides","volume":"23","author":"P\u00edcha","year":"2017","journal-title":"Journal of Peptide Science"},{"key":"10.1016\/j.bmcl.2023.129308_b0185","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1517\/13543784.6.10.1479","article-title":"Dual \u03b2-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment","volume":"6","author":"Bryskier","year":"1997","journal-title":"Expert Opin. Investing. Drugs"},{"key":"10.1016\/j.bmcl.2023.129308_b0190","unstructured":"https:\/\/www.aatbio.com\/tools\/ic50-calculator."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23001865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23001865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:48:29Z","timestamp":1760773709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23001865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"alternative-id":["S0960894X23001865"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129308","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of novel ciprofloxacin-avibactam conjugates for the development of second-generation non-\u03b2-lactam-\u03b2-lactamase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129308"}}